Cargando…

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial

Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hammersen, J., Birndt, S., Döhner, K., Reuken, P., Stallmach, A., Sauerbrey, P., La Rosée, F., Pfirrmann, M., Fabisch, C., Weiss, M., Träger, K., Bremer, H., Russo, S., Illerhaus, G., Drömann, D., Schneider, S., La Rosée, P., Hochhaus, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457200/ https://www.ncbi.nlm.nih.gov/pubmed/37507425 http://dx.doi.org/10.1038/s41375-023-01979-w

Ejemplares similares

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)

The impact of specific cytokine directed treatment on severe COVID-19
por: Reuken, P. A., et al.
Publicado: (2021)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation
por: La Rosée, P., et al.
Publicado: (2020)

Erratum zu: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter Hyperferritinämischer Inflammation
por: La Rosée, P., et al.
Publicado: (2020)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

Hemophagocytic Syndrome-Associated Intravascular Large B-cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease Treated With Autologous Stem Cell Transplantation Using a Modified TEAM Regimen
por: Kama, Kudret, et al.
Publicado: (2022)

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
por: Mascarenhas, John, et al.
Publicado: (2023)

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
por: Heidel, F., et al.
Publicado: (2020)

Die hämophagozytische Lymphohistiozytose bei kritisch kranken Patienten
por: Eichenauer, D. A., et al.
Publicado: (2021)

Anticipating pulmonary complications after thoracotomy: the FLAM Score
por: Leo, Francesco, et al.
Publicado: (2006)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
por: Ali, Haris, et al.
Publicado: (2023)

P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL
por: Gerds, Aaron T., et al.
Publicado: (2023)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

Die hämophagozytische Lymphohistiozytose bei kritisch kranken Patienten
por: Eichenauer, Dennis A., et al.
Publicado: (2021)

An orphan kinesin controls trypanosome morphology transitions by targeting FLAM3 to the flagellum
por: An, Tai, et al.
Publicado: (2018)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
por: Gupta, V., et al.
Publicado: (2022)

LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
por: Frietsch, Jochen J., et al.
Publicado: (2014)

RuX: A Novel, Flexible, and Sensitive Mifepristone-Induced Transcriptional Regulation System
por: Meinzinger, Anne, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry
por: Birndt, Sebastian, et al.
Publicado: (2020)

Rapid Treatment of Leukostasis in Leukemic Mantle Cell Lymphoma using Therapeutic Leukapheresis: A Case Report
por: Nguyen, Xuan Duc, et al.
Publicado: (2011)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

Recruitment of precarious families in an interventional study: Lessons from the French “Fruits and vegetables at home” (FLAM) trial
por: Buscail, Camille, et al.
Publicado: (2018)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

Folgen nach SARS-CoV-2-Infektion einschließlich Post-COVID-Syndrom
por: Quickert, Stefanie, et al.
Publicado: (2023)

Modulation of flagellum attachment zone protein FLAM3 and regulation of the cell shape in Trypanosoma brucei life cycle transitions
por: Sunter, Jack D., et al.
Publicado: (2015)

flam piRNA precursors channel from the nucleus to the cytoplasm in a temporally regulated manner along Drosophila oogenesis
por: Dennis, Cynthia, et al.
Publicado: (2019)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
Publicado: (2020)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
por: -, -
Publicado: (2020)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
por: Rashaan, Zjir M., et al.
Publicado: (2019)

The Perception and Estimation of Others' Pain according to Children
por: Grégoire, Mathieu, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2s406d8170qq6rfjv5q117gs74